Several trials are ongoing, which are listed in ClinicalTrials.org to study 18F-FTT as a PARP1 tracer pre-/post-treatment, in a wide range of cancers like ovarian (NCT03604315, NCT02637934), breast (NCT03846167), pancreatic (NCT03492164), prostate (NCT03334500), and GBM patients (NCT04221061). Here, PARP1 is linked to cancer.